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Abstract
Background: Studies have noted variations in the cost-effectiveness of school-located influenza vaccination (SLIV), but
little is known about how SLIV’s cost-effectiveness may vary by targeted age group (e.g., elementary or secondary
school students), or vaccine consent process (paper-based or web-based). Further, SLIV’s cost-effectiveness may be
impacted by its spillover effect on practice-based vaccination; prior studies have not addressed this issue.
Methods: We performed a cost-effectiveness analysis on two SLIV programs in upstate New York in 2015–2016: (a)
elementary school SLIV using a stepped wedge design with schools as clusters (24 suburban and 18 urban schools)
and (b) secondary school SLIV using a cluster randomized trial (16 suburban and 4 urban schools). The cost-per-
additionally-vaccinated child (i.e., incremental cost-effectiveness ratio (ICER)) was estimated by dividing the incremental
SLIV intervention cost by the incremental effectiveness (i.e., the additional number of vaccinated students in
intervention schools compared to control schools). We performed deterministic analyses, one-way sensitivity analyses,
and probabilistic analyses.
Results: The overall effectiveness measure (proportion of children vaccinated) was 5.7 and 5.5 percentage points
higher, respectively, in intervention elementary (52.8%) and secondary schools (48.2%) than grade-matched control
schools. SLIV programs vaccinated a small proportion of children in intervention elementary (5.2%) and secondary
schools (2.5%). In elementary and secondary schools, the ICER excluding vaccine purchase was $85.71 and $86.51 per-
additionally-vaccinated-child, respectively. When additionally accounting for observed spillover impact on practice-
based vaccination, the ICER decreased to $80.53 in elementary schools -- decreasing substantially in secondary schools.
(to $53.40). These estimates were higher than the published practice-based vaccination cost (median = $25.50,
mean = $45.48). Also, these estimates were higher than our 2009–2011 urban SLIV program mean costs ($65) due to
additional costs for use of a new web-based consent system ($12.97 per-additionally-vaccinated-child) and higher
project coordination costs in 2015–2016. One-way sensitivity analyses showed that ICER estimates were most sensitive
to the SLIV effectiveness.
Conclusions: SLIV raises vaccination rates and may increase practice-based vaccination in primary care practices. While
these SLIV programs are effective, to be as cost-effective as practice-based vaccination our SLIV programs would need
to vaccinate more students and/or lower the costs for consent systems and project coordination.
Trial Registration: ClinicalTrials.gov NCT02227186 (August 25, 2014), updated NCT03137667 (May 2, 2017).
Keywords: School-located vaccination program, Influenza vaccination, Adolescents, School-age children, Web-based
consent form system, Cost-effectiveness analysis, Incremental cost-effectiveness ratio
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Background
Seasonal influenza can cause serious morbidity, mortal-
ity, and financial burden [1, 2]. Although the United
States Advisory Committee on Immunization Practices
(ACIP) has recommended universal annual seasonal in-
fluenza vaccination for all children aged 6 months to 18
years since 2008 [3], vaccination rates among school-
aged children have remained low with little improve-
ment since the 2013–2014 season [4]. For the 2016–17
influenza season, only 60% of 5–12 year olds and 49% of
13–17 year olds received influenza vaccination [4].
One barrier to influenza vaccination is the need for an
additional medical visit for vaccination, creating a bur-
den for children and parents [5]. This burden could the-
oretically be reduced by providing influenza vaccination
during school hours, here-in referred to as school-
located influenza vaccination (SLIV) [6]. Yet, despite
general support for SLIV by pediatricians [7, 8] and par-
ents [9], less than 5% of all child influenza vaccinations
were administered at schools during the 2011–2014 sea-
sons [10].
To increase vaccinations in SLIV programs, further
data on the effectiveness, the cost-effectiveness, and the
financial sustainability of SLIV programs are needed [11,
12]. In our four recent randomized controlled trials
(RCTs) of SLIV during the 2009–2010, 2010–2011,
2014–2015, and 2015–2016 vaccination seasons, we
found that SLIV increased overall influenza vaccination
rates by 5 to 16 percentage points among elementary
school children [13, 14] and 5 percentage points among
suburban secondary school children [15]. In our model,
SLIV clinics were held after November to allow primary
care practices to vaccinate many patients before SLIV
clinics were held. This ensures that SLIV is a comple-
ment to, rather than a substitute for, practice-based vac-
cination [15, 16]. In our previous cost-effectiveness
analysis we found that SLIV cost approximately $65–$73
[in 2015 US dollars] per vaccinated child during the
2009–2011 seasons [17, 18]. Thus, our past SLIV pro-
grams were more expensive (i.e., less cost-effective) than
(1) practice-based influenza vaccination (median/mean:
approximately $25.50/$45.48 per vaccinated child) [17,
19] and (2) seasonal SLIV programs that used other
models (e.g., providing donated vaccine without billing
or administering vaccine early in the vaccination sea-
son) [20–24].
This paper reports the cost-effectiveness analysis (CEA)
of SLIV programs in elementary schools [16] and second-
ary schools (middle and high schools) [15] conducted dur-
ing the 2015–2016 vaccination season. This paper is novel
for several reasons. To our knowledge, this is the first
CEA that includes SLIV performed in secondary schools
(i.e., we and others have performed CEA for SLIV in elem-
entary schools, but not in middle or high schools).
Additionally, this is the first CEA of an SLIV program
using an innovative web-based informed consent (here-
after called “web-consent”) system. Web-consent might
theoretically reduce SLIV implementation costs by redu-
cing expenses related to copying and handling paper
consent forms. If a large proportion of parents use the
web-consent that could lower SLIV costs, and SLIV
might be more attractive to communities.
The third reason this paper is novel is that we evalu-
ated how the cost-effectiveness of a specific SLIV model
can vary based on the potential impact of SLIV upon
practice-based vaccination (herein called “spillover”).
Spillover can be either positive spillover (increasing
practice-based vaccination) or negative spillover (substi-
tuting practice-based vaccination with SLIV) [14–18].
Negative spillover could be a serious barrier to collab-
orative vaccination delivery between SLIVs and practice-
based vaccination [8]. For instance, a national survey
among pediatricians reported that 85% of respondents
agreed it would be difficult to estimate how much vac-
cine to order if large numbers of children received influ-
enza vaccine at SLIVs [8]. This is important because
practices have to bear financial loss if they are left with
unused and non-returnable vaccines [8, 25].
Positive or negative spillover may reflect which par-
ticular model of SLIV is used. Specifically, our model
started SLIV clinics after November to allow practices to
vaccinate as many children as possible first—this would
favor positive spillover. Other SLIV programs that
started SLIV clinics in early October might result in
more of negative spillover or substitution. This is an im-
portant point that has not been addressed in prior pa-
pers. A key advance in our study is that our SLIV
model, while perhaps vaccinating fewer children in
school, leads to positive spillover rather than substitu-
tion [8, 14–16, 25].
Positive spillover may be related to communication
with parents about flu vaccination, with the provision
of information about the SLIV program serving as a
reminder to parents to take their children to their
primary care practices during the vaccination season
(even after November when SLIV clinics were held).
When positive spillover occurs, measuring the SLIV’s
effectiveness by the number of students vaccinated
only at SLIV clinics would worsen our SLIV’s cost-
effectiveness.
The likelihood and the magnitude of negative spillover
depend on the timing of implementing an SLIV pro-
gram. If an SLIV program is implemented earlier in the
influenza vaccination season (e.g., September through
November), both the likelihood and the magnitude of
negative spillover would be larger than those imple-
mented after November -- thus improving the SLIV pro-
gram’s cost-effectiveness.
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When using an SLIV effectiveness measure of the in-
cremental vaccination rate in SLIV schools compared to
control schools (including potential spillover), SLIV cost-
effectiveness may vary depending on the direction (ei-
ther positive or negative) and the magnitude of spillover.
Although we previously estimated the cost-effectiveness
of our 2009–2010 SLIV program accounting for an
observed spillover, we made a simplified assumption that
vaccine administration in primary care practices due to
spillover did not incur any cost [17]. Instead, the current
study assigned the vaccine administration costs related
to spillover based on the administration cost at primary
care practices [19] (the site at which more than 95% of
non-SLIV vaccinations occurred) [16].
Hypotheses:
1) Elementary school SLIV will be more cost-effective
than secondary school SLIV. This is based upon the
SLIV literature suggesting greater challenges in
implementing SLIV (i.e., lower effectiveness) for
older children [12]. These challenges to SLIV effect-
iveness include, for example, less timely receipt of
school communication by older students’ parents
and less parental perception of the older students’
vulnerability to serious infection.
2) SLIV will create positive spillover. We hypothesize
that because parents of students in SLIV schools are
exposed to the SLIV-related cues to action (e.g.,
fliers), they are likely to have their child vaccinated
either at school or primary care practices, creating
positive spillover.
3) This positive spillover will substantially reduce the
number of children potentially vaccinated at school.
Consequently, the cost-effectiveness of our SLIV
program will be (a) worsened if the effectiveness
measure excludes children vaccinated at primary
care practices (i.e., lower effectiveness) and (b) im-
proved if the effectiveness includes children vacci-
nated at primary care practices (i.e., higher
effectiveness). Therefore, two effectiveness measures
were adopted in our analysis, detailed in the
Methods.
4) Elementary and secondary school SLIV will have
higher costs and thus be less cost-effective than
practice-based influenza vaccination, without ac-
counting for spillover upon practice-based vaccin-
ation or without accounting for indirect costs (i.e.,
parents’ time costs) that reflect a broader societal
perspective. However, accounting for these factors,
the cost-effectiveness of SLIV may begin to ap-
proach that of practice-based vaccination. To test
this assumption, our study defined “the standard-
ized program cost” as all costs needed to provide flu
vaccination (e.g., reminders), except the cost to
purchase vaccine doses. Therefore, for testing hy-
pothesis 4, we applied the common definition of
“the standardized program cost” to calculate
practice-based vaccination costs from our previ-
ously published studies [17, 19]. Hypothesis 4 was
developed because the standardized program cost
of our SLIV programs explicitly included costs of
reminders and informed consent (including the de-
velopment of the web-consent system) although
that of primary care practices did not explicitly in-
clude these items [17, 19].
5) This SLIV program that uses a novel web-consent
system (including the option to print and turn in a
paper consent form) will be more cost-effective
than SLIV with a paper-only consent system. We
expected that the 2015–2016 web-consent system
would reduce the printing, distribution, and hand-
ling costs for paper-based consent forms that were
observed in our 2009–2011 SLIV programs [18]
and would contribute to lower costs of SLIV.
Methods
Study design of primary data collection
We collected primary data from two SLIV programs lo-
cated in elementary schools [16] and secondary schools
[15] in Monroe County, New York. Regarding the data
from elementary schools, we used a stepped wedge study
design with schools as clusters. In 2014–2015, elemen-
tary schools were randomly allocated to SLIV or control
(control n = 10,185 students in 12 suburban and 9 urban
schools in Table 1) [16]. Then in 2015–2016, all of the
elementary schools were assigned to SLIV (intervention
n = 21,696 in 24 suburban and 18 urban schools). In sec-
ondary schools, we implemented a cluster-randomized
trial in 2015–2016 [15]. After selecting 10 pairs of sec-
ondary schools (with identical grade levels within pairs),
we randomly allocated schools within pairs either to
SLIV (intervention n = 9488; in 8 suburban and 2 urban
schools) or control (control n = 8850; in 8 suburban and
2 urban schools) [15].
For these two SLIV programs, we notified parents
using emails (suburban schools only) or backpack fliers
(at both urban and suburban schools). Paper-based vac-
cination consent forms were available for all schools;
these paper-based consent forms included a link to the
web-consent system. Web-based consent in our SLIV
program worked as follows. Parents received an email
about the SLIV program, and the email contained a link
to a website. Backpack fliers also contained a written
link to the website. The website itself described the SLIV
program and included a fillable consent form, which
mirrored the Monroe County Department of Public
Health (MCDPH) influenza vaccination consent form.
Parents completed this form and indicated “yes” to
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parent consent for influenza vaccination. The informa-
tion from the website was transmitted to personnel at
the MCDPH who checked the New York Immunization
Information System (NYSIIS) just prior to the SLIV
clinic to ensure the child had not been vaccinated and
also reviewed doctor and insurance information.
We partnered with the MCDPH (hereafter called
“vendor”), which delegated nurses to administer SLIV
vaccinations on a single date per school. We used the
NYSIIS data to determine influenza vaccine receipt. Our
study’s endpoints were the dates when we matched chil-
dren’s names and birthdates obtained from the school
directories with NYSIIS records to obtain influenza vac-
cination data: April 1, 2016 for secondary schools [15]
and July 31, 2016 for elementary schools [16].
Our earlier publications reported the SLIV program’s
effectiveness only, not cost-effectiveness [15, 16]. For in-
stance, the SLIV program’s overall effectiveness measure
(proportion of children vaccinated “Anywhere”) was 5.8
and 5.5 percentage points in elementary and secondary
schools, respectively, suggesting a moderate impact of
SLIV in both elementary and secondary schools [15, 16].
As another effectiveness measure, SLIV programs vacci-
nated 4.9 and 2.5% of children enrolled in intervention
elementary and secondary schools, respectively [15, 16].
It should be noted that the numbers of students vacci-
nated in the SLIV programs were slightly higher in this
manuscript’s Table 1, since the continuing confirmation
process of vaccination status identified additionally vac-
cinated students.
Since influenza immunization rates vary by poverty
status [26], we collected data about the percentage of
students eligible for free/reduced cost school lunch (i.e.,
below 185% of the federal poverty level (FPL) [27]) in
2014 (overall 28 and 90% for suburban and urban
schools, respectively). This was used among factors for
pairing schools within each school district [14]. Com-
pared to the national average of being below 200% FPL
(28% of the total population in 2014) [28], our study
population’s socio-economic status was slightly lower in
suburban schools, but much lower in urban schools.
The Research Subjects Review Board of the University
of Rochester approved this study and the protocols for
both SLIV programs.
Cost-effectiveness analysis (CEA)
We developed simple decision tree models to conduct
CEAs with the time horizon of one vaccination season
(i.e., within 1 year) from the societal perspective, follow-
ing the guideline by Drummond et al. [29]. Our cost-
effectiveness analysis models derived all of the effective-
ness parameters and most of the cost parameters from
our primary data described above. We calculated the in-
cremental cost-effectiveness ratio (ICER) through divid-
ing the incremental cost (i.e., the difference in cost to
vaccinate in intervention schools minus that in control
schools) by the incremental effectiveness (i.e., the add-
itional number of vaccinated students in intervention
schools compared to control schools irrespective of
where students were vaccinated after standardizing the
samples sizes of intervention and control schools). The
ICER’s unit is dollars-per-additionally-vaccinated-child.
We defined effectiveness and cost measures below, fol-
lowing our earlier studies [17, 18].
Our CEAs included two sets of deterministic analyses
(Figs. 1 and 2). To address the uncertainties of model
parameters, we performed a one-way sensitivity analysis
and a probabilistic analysis with Monte Carlo simula-
tions by assigning parameters’ distributions (Table 2).
For instance, a triangular distribution (mode = 4.4%,
minimum = 2.5%, maximum = 5.2%) was assumed for the
vaccination rate at SLIV in all schools (Table 2, First row
Table 1 Vaccination rates in school-located influenza vaccination program and control schools in 2015–2016
All Schoolsc Elementary Schoolsc Secondary Schools
SLIV schools b Control schoolsc SLIV schools b Control schoolsc SLIV schools b Control schools
Students % Total
Students
Students % Total
Students
Students % Total
Students
Students % Total
Students
Students % Total
Students
Students % Total
Students
TOTAL
STUDENTS
31,184 100% 19,035 100% 21,696 100% 10,185 100% 9488 100% 8850 100%
Not
vaccinated
15,153 48.6% 10,457 54.9% 10,238 47.2% 5385 52.9% 4915 51.8% 5072 57.3%
Total
vaccinated
16,031 51.4% 8578 45.1% 11,458 52.8% 4800 47.1% 4573 48.2% 3778 42.7%
Vaccinated in
“practices”a
14,665 47.0% 8578 45.1% 10,331 47.6% 4800 47.1% 4334 45.7% 3778 42.7%
Vaccinated at
SLIV b
1366 4.4% n/a n/a 1127 5.2% n/a n/a 239 2.5% n/a n/a
a “Practice” indicates the vaccinations’ administration setting other than SLIV clinics, almost always (> 95%) primary care practices [16]
b SLIV: School-located influenza vaccination
c Because of our stepped wedge trial study design, control schools for elementary schools in 2015–2016 were the control schools in 2014–2015
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and first column). Monte Carlo simulations allow us to
provide the mean and the 95% probabilistic confidence
interval (PCI) of the ICER estimates. All simulation ana-
lyses used Treeage Pro 2018 (https://www.treeage.com/).
Effectiveness measure
We defined two effectiveness measures in Table 2. Our
primary measure (illustrated in Fig. 1) is the difference
between the proportion of students vaccinated “Any-
where” among students enrolled in control vs. interven-
tion schools. “Anywhere” includes both vaccinations
administered at the SLIV program and those in “prac-
tices.” “Practice” indicates the vaccinations’ administra-
tion setting other than SLIV clinics, almost always (>
95%) primary care practices [16]. Our definition of “Any-
where” aligned with the past publications [14–18]. This
effectiveness measure was used because the SLIV activ-
ities could have motivated parents to have their children
vaccinated at either a primary care practice or via the
SLIV programs.
In Fig. 1, our primary measure is depicted as control
school student vaccination (labeled P_Ctrl) vs. interven-
tion school student vaccination -- either at schools (la-
beled as P_SLIV/(1- P_Ctrl - P_Spillover) among
students not vaccinated in practices, (i.e., P_SLIV among
all students) or in primary care “practices” (labeled P_
Ctrl + P_Spillover). As defined earlier, “spillover” is the
potential impact of SLIV upon practice-based vaccin-
ation. These model parameters, P_SLIV and P_Spillover,
indicate that the SLIV program increased likelihood of
vaccination at SLIV and in “practices” for each student
enrolled in all SLIV schools.
Our secondary and narrower measure (explained in
Fig. 2) is the difference between the proportion of stu-
dents vaccinated in SLIV vaccination clinics among stu-
dents enrolled in intervention schools (P_SLIV in Fig. 2)
vs. control schools (i.e., zero probability of vaccination at
the SLIV program).
Our primary measure captures a more comprehensive
effect of the SLIV program than the second one,
Fig. 1 Decision tree model to conduct a cost effectiveness analysis for school-located influenza vaccination program in 2015–2016, accounting
for potential spillover. Model parameters are defined in Table 2; # is a probability defined by other parameters so that each chance node (○ in
the tree) has the summed probability of 1
Fig. 2 Decision tree model to conduct a cost effectiveness analysis for school-located influenza vaccination program in 2015–2016, without
accounting for potential spillover. Model parameters are defined in Table 2; # is a probability defined by other parameters so that each chance
node (○ in the tree) has the summed probability of 1
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addressing a potential spillover effect (P_Spillover in Fig.
1) and, hence, potential concern for coordinating with
local primary care practices [8, 25]. To our best know-
ledge, none of past SLIV studies used this comprehen-
sive measure [20–24, 34, 35]. Our secondary and
narrower measure was used to compare with these past
SLIV studies.
Cost measures
We estimated all costs in 2015 US dollars, adjusting
for changes in the consumer price index (CPI) when
necessary [36]. We estimated three components of
“Program Costs” incurred by the SLIV program: (A)
school costs, (B) project coordination costs, and (C)
vendor costs, as well as one “indirect cost” averted by
having the SLIV program: (D) averted parents’ costs
(i.e., parents’ costs to accompany a child to a primary
care practice visit for the child’s influenza vaccin-
ation). We defined “Total Cost” as “Program Costs”
(A + B + C) minus averted parent costs (D).
Program cost components
Component A (school costs) included non-labor mater-
ial costs (e.g., supplies and expenses for distributing
information to parents), labor costs incurred by school
staff (e.g., attending preparatory meetings and escorting
students), and the web-consent system cost. We esti-
mated labor costs by multiplying the school staff hours
self-reported in real-time surveys by the national median
wage of a relevant job category as of May 2015 [37]. The
annual cost for the web-consent system (shared by all
suburban intervention schools) included the annual
maintenance cost ($8000) and the upfront equipment
cost (i.e., IT costs, averaging the upfront equipment cost
of $68,000 over 7 years, i.e., $9714 per year).
Component B (project coordination costs) com-
prised the cost involved with coordinating activities,
but excluded the costs regarding research and
evaluation.
Component C (vendor costs) included the vendor’s
vaccination administration cost, including (a) labor
costs to administer SLIV vaccinations and to bill in-
surers and (b) material costs including costs for vac-
cine purchase, the refrigerator for vaccines, and
medical supplies in primary analyses. Following the
definition of “the standardized program cost,” this
Cost Component C did not include the vendor’s vac-
cine purchase cost.
Table 2 Parameters for Cost-Effectiveness Analysis Decision Model
Parameter (Name in Decision Trees in Figs. 1 and 2) All Schoolsd Elementary
Schoolse
Secondary
Schoolsf
Effectiveness Parameters
Vaccination Rate at SLIV clinics only among Children in SLIV Schools (P_SLIV) 4.4%
(2.5%, 5.2%)
5.2%
(3.2%, 8.1%)
2.5%
(2.0%, 2.6%)
Incremental Vaccination Rate in “Practices” a among Children in SLIV Schools, compared to
Vaccination Rate among Children in Control Schools (P_Spillover)
1.9%
(0.5%, 3.0%)
0.5%
(−1.4%g, 1.4%)
3.0%
(2.9%, 5.0%)
Vaccinated at Practices among Children in Control Schools (P_Ctrl) 45.1% 47.1% 42.7%
Cost Parameters for All Children in SLIV [$ per eligible child] (Cost_AB = A + B defined below)
(A) School cost [$ per eligible child] $1.00
($0.59, $1.17)
$1.17
($1.12, $1.26)
$0.59
($0.58, $0.63)
(B) Project cost [$ per eligible child] $1.70
($0.98, $2.02)
$2.02
($1.82, $2.22)
$0.98
($0.88, $1.08)
Cost Parameters for Children Vaccinated at SLIV [$ per vaccinated child] (Cost_C = C for “Subtotal Costs”; and Cost_C = C - D for “Total Costs”
defined below)
(C) Vaccine administration $24.30 ($21.87, $26.73)
(D) Averted parents’ costs (i.e., to visit primary care practices for a child’s influenza vaccination)b $36.81 ($33.13, $40.49)
Cost Parameters of Primary Care Practice [$ per vaccinated child] (Cost_Practice) c $25.50 ($15.68, $45.48)
All parameters were derived from our original study unless otherwise defined below
SLIV: School-located influenza vaccination
a “Practice” indicates the vaccinations’ administration setting other than SLIV clinics, almost always (> 95%) primary care practices [16]
b This cost component (D) included the cost of parents’ time [30–32] and transportation [33], which does not comprise any medical expenditure, either paid by
parents or incurred at primary care practices
c A range of values was derived from our previously published practice-based vaccination cost (25 percentile = $15.68, median = $25.50, and mean = $45.48 [per-
vaccinated-child]; Of note, mean (=$45.48) was comparable to 75 percentile (=$45.38)) [17, 19]
d A range of values was derived from the variation between elementary schools and secondary schools
e A range of values was derived from the variation between urban and rural schools within elementary schools
f A range of values was derived from the variation between urban and rural schools within secondary schools
d,e,f A range of values were used as minimum and maximum values to define a triangular distribution (where a mode value is a point estimate) for a parameter
distribution used in a probabilistic analysis with Monte Carlo simulations
g A negative value (− 1.40%) presents negative spillover observed among urban elementary schools
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Component D estimated the averted cost for a house-
hold with a child vaccinated through SLIV compared to
a household with a child vaccinated outside SLIV. These
cost estimates were assumed to be constant across all
households. We followed our previous studies [17, 18] in
estimating averted parent costs (D), which included par-
ents’ time cost [30–32] and transportation cost [33].
This Cost Component D, $36.81, does not comprise any
medical expenditure, either paid by parents or incurred
at primary care practices. Of note, this Cost Component
D was incorporated in the evaluation of the costs to the
SLIV program that accounts for positive spillover.
Comparison with practice-based vaccination
Our a priori assumption was that SLIV would be less
cost-effective than practice-based vaccination if the esti-
mated ICER for SLIV were above the median/mean
($25.50/$45.48) cost-per-additionally-vaccinated child
for practice-based influenza vaccination as reported in
our past study [17, 19]. To make this comparison, re-
gardless of the proportion of VFC-eligible children in
each vaccination site, we excluded the vaccine purchase
cost from both SLIV costs and primary care practices’
costs [17, 19] to be comparable to our “standardized
program cost” defined earlier. For another comparison,
we subtracted the averted parents’ costs (Component
D = $36.81) from the SLIV Program Costs.
Results
Cost effectiveness analysis (CEA) (Table 3)
Table 3 shows ICER estimates of SLIV by grade group-
ing (all, elementary, and secondary) and by vaccination
site (SLIV clinic, Anywhere), which enable us to com-
pare the SLIV program’s economic efficiency (a) between
schools and (b) with that of practice-based vaccination.
Table 3 presents ICERs based on both deterministic and
probabilistic analyses. These deterministic and probabil-
istic analyses did not differ qualitatively in terms of test-
ing our hypotheses. Therefore, the following results
section mainly discusses the ICER estimates based on
deterministic analyses.
Comparison between elementary and secondary schools
The ICER estimates were comparable between elemen-
tary and secondary schools when spillover was not con-
sidered. For example, Table 3’s columns of “SLIV” shows
that the ICER estimates based on the ‘Subtotal Cost’
(Components A + B + C) were around $86 per-
additionally-vaccinated-child in both elementary and
secondary schools. However, when spillover was consid-
ered, these ICER estimates (in columns of “Anywhere”)
indicated that the SLIV programs in secondary schools
were more cost-effective than those in elementary
schools, regardless of the consideration of Component
D.
Comparison with practice-based vaccination
As reported above, the ICER estimates (based on Sub-
total Cost (Components A + B + C)) were at least $53.40
and $86.51 [per-additionally-vaccinated-child] with and
without accounting for spillover, respectively. These esti-
mates were higher than those previously reported for
vaccination in primary care practices (mean = $45.48)
[17, 19].
When considering indirect averted parent costs (D), our
findings changed dramatically. Namely, the ICER esti-
mates (based on Total Cost: Components A + B + C – D,
considering spillover) in secondary and all schools
($36.57–$41.76) were lower than the mean cost of vaccin-
ation at primary care practices (Table 3). Therefore, our
Table 3 Estimated Incremental Cost-effectiveness Ratio (ICER) [$ per-additionally-vaccinated-child] of school-located influenza
vaccination program in 2015–2016 [2015 dollar value]
Vaccination location All Schools Elementary Schools Secondary Schools
SLIV b Anywhere c SLIV b Anywhere c SLIV b Anywhere c
ICER using SUBTOTAL COST: (A + B + C)
Deterministic Analysis $85.84 $67.17 $85.71 $80.53 $86.51 $53.40
Probabilistic Analysis a (95% PCI) $87.95
($70.26, $112.92)
$68.89
($53.39, $87.24)
$86.67
($66.82, $108.54)
$84.18
($64.20, $118.08)
$91.38
($84.41, $100.98)
$53.53
($45.57, $61.71)
ICER using TOTAL COST: (A + B + C)-(D)
Deterministic Analysis $49.03 $41.76 $48.90 $46.89 $49.70 $36.57
Probabilistic Analysis a (95% PCI) $50.17
($32.46, $77.40)
$43.55
($30.14, $61.10)
$47.98
($29.39, $73.91)
$47.70
($29.44, $75.90)
$54.42
($46.72, $63.59)
$38.73
($31.79, $47.38)
All cost estimates were expressed in 2015 dollar value
Cost components (A, B, C, D) are defined in Table 2
a Probabilistic model used the distributions of model parameters defined in Table 2 to perform Monte Carlo simulations to provide the mean and 95%
probabilistic confidence interval (PCI) of estimates
b SLIV: School-located influenza vaccination
c “Anywhere” includes both vaccinations administered at the SLIV program and those in “practices.” “Practice” indicates the vaccinations’ administration setting
other than SLIV clinics, almost always (> 95%) primary care practices [16]
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fourth hypothesis – the cost-effectiveness of SLIV may
begin to approach that of practice-based vaccination when
accounting for spillover and indirect costs – was
supported.
Comparison with our past SLIV program without the web-
consent system
The ICER estimates (based on Subtotal Cost (Compo-
nents A + B + C) without accounting for spillover) were
$85.71 per vaccinated child and $86.51 in elementary
and secondary schools, respectively. All of these esti-
mates were higher than our 2009–2011 SLIV cost esti-
mates ($65.14–$65.34). The differences were mainly
explained by two costs in 2015–2016: additional cost for
web-consent ($0.57 per eligible child and $12.97 per-
additionally-vaccinated-child in all SLIV schools; not
presented in tables) and higher project coordination cost
($1.70 per eligible child and $38.81 per-additionally-
vaccinated-child in all SLIV schools, which was in part
related to additional work for the web-consent system;
not presented in tables) for each child vaccinated. The
web-consent system did not appear to improve SLIV’s
economic efficiency except when accounting for spill-
over. Specifically, when considering spillover, the ICER
estimates (based on Subtotal Cost (Components A + B +
C)) were higher in 2009–2010 ($72.56), but lower in
2010–2011($63.35), and varied by grade grouping in
2015–2016: all schools ($67.17), elementary schools
($80.53) and secondary schools ($53.40). Thus, our fifth
hypothesis – SLIV becomes more cost-effective with the
use of the web-consent system – was partly supported
only when spillover was considered.
One-way sensitivity analysis
Table 4 presents the results of one-way sensitivity ana-
lysis of CEA for the SLIV programs in all schools. The
ICER estimates were most sensitive to the effectiveness
parameters (particularly the primary effectiveness meas-
ure, i.e., vaccination rate at SLIV only among children in
SLIV schools) but robust to cost parameters. Still, all
ICER estimates using Subtotal Cost in Table 4 were
higher than the mean cost of practice-based vaccination
($45.48 per vaccinated child). Conversely, ICER esti-
mates, using Total Cost, can be lower than this mean
cost for each of seven parameters in Table 4.
Break-even analysis
We performed two sets of break-even analyses for CEA:
(1) Based on the Subtotal Cost (A + B + C), we
estimated the proportion of students vaccinated at
SLIV necessary for the cost in SLIV programs and
Table 4 One-way sensitivity analyses for Incremental Cost-effectiveness Ratio (ICER) estimates [$ per-additionally-vaccinated-child] of
school-located influenza vaccination program in 2015–2016 [2015 dollar value]
Parameters (Point Estimate) Range ICER using Subtotal
Cost b
ICER using Total
Cost b
SLIV c Anywhere
d
SLIV c Anywhere
d
1 Vaccination Rate at SLIV clinics only among Children in SLIV Schools (4.40%) 2.0% $188.02 $76.74 $151.21 $65.13
8.10% $46.42 $52.22 $9.21 $5.22
2 Incremental Vaccination Rate in “Practices” a among Children in SLIV Schools, compared to
Vaccination Rate among Children in Control Schools (1.90%)
−1.4% NA $114.19 NA $60.09
5.0% NA $53.68 NA $36.49
3 SLIV: School cost (= A) [$ per eligible child] ($1.00) $0.58 $76.35 $60.61 $39.54 $35.19
$1.26 $91.87 $71.33 $55.06 $45.91
4 SLIV: Project cost (= B) [$ per eligible child] ($1.70) $0.98 $69.50 $55.88 $32.69 $30.46
$2.02 $93.24 $72.28 $56.43 $46.86
5 SLIV: Vaccine administration cost (=C) [$ per vaccinated child] ($24.30) $21.87 $83.42 $65.49 $46.60 $40.07
$26.73 $88.28 $68.85 $51.46 $43.43
6 Averted parents’ costs (i.e., to visit primary care practices for a child’s influenza vaccination)
(=D) [$ per vaccinated child] ($36.81)
$33.13 NA NA $52.71 $44.29
$40.49 NA NA $45.35 $39.21
7 Vaccine Administration Cost of Primary Care Practice [$ per vaccinated child] ($25.50) $15.68 NA $64.13 NA $38.71
$45.48 NA $73.35 NA $47.93
NA Not Applicable
a “Practice” indicates the vaccinations’ administration setting other than SLIV clinics, almost always (> 95%) primary care practices [16]
b Cost components (Subtotal cost or Total cost) are defined in Table 2
c SLIV: School-located influenza vaccination
d “Anywhere” includes both vaccinations administered at the SLIV program and those in “practices.” “Practice” indicates the vaccinations’ administration setting
other than SLIV clinics, almost always (> 95%) primary care practices [16]
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primary care practices to be equivalent, without
including averted parents’ costs to visit a medical
practice (D). Assuming no change in the magnitude
of spillover, this would be achieved if the
proportion of children vaccinated in SLIV increased
from the actual levels in all schools (4.4%),
elementary (5.2%) and secondary (2.5%) to at least
15.1, 17.5 and 8.8%, respectively.
(2) Based on the Total Cost [(Program Costs – parent
costs) = (A + B + C – D)], we estimated the level of
vaccination at SLIV necessary for SLIV to be cost-
saving to society (including parents’ averted costs).
Assuming no change in the magnitude of spillover,
this would be achieved if the proportion of children
vaccinated in SLIV clinics increased to at least the
following levels: all schools = 11.6%, elementary
schools = 12.5%, secondary schools = 8.0%.
Discussion
SLIV modestly raised vaccination rates in both elemen-
tary schools and secondary schools. While these SLIV
programs are effective, to be as cost-effective as
practice-based vaccination our SLIV programs would
need to vaccinate more students and/or lower the costs
for consent systems and project coordination. Further,
SLIV caused positive spillover, increasing practice-based
vaccination among suburban children; this improved the
effectiveness and cost-effectiveness of SLIV and should
be addressed by future studies. Nonetheless, SLIV was
less cost-effective than practice-based vaccination when
considering the cost-per-additionally-vaccinated child,
but equally or more cost-effective when additionally
considering indirect costs (parental time lost from work)
. Finally, our ICER estimates based on deterministic ana-
lyses were robust to one-way sensitivity analyses and
probabilistic analyses.
Hypothesis 1: SLIV in secondary schools and comparison
with elementary school SLIV
This is the first published CEA that we can find of a
large-scale RCT of an SLIV program administered in
secondary schools. Our SLIV program methods in sec-
ondary and elementary schools were similar with respect
to the procedures used for SLIV vaccine clinics, the use
of a shared web-consent system and shared project co-
ordination staff. The results – both overall effectiveness
and cost-effectiveness – were also similar for the two
groups. It should be noted that the magnitude of the
overall effectiveness in secondary schools (5.5% in Table
2, combining first and second rows) was smaller than
what was noted in our past RCTs in elementary schools
in 2009–2011 [18] and in the literature [12]. Also, the
second effectiveness measure (the proportion of school
children vaccinated at an SLIV clinic) was lower in
secondary schools (2.5% in Table 2, first row) than in
elementary schools (5.2% in Table 2, first row). The
latter finding appears consistent with a review article in-
dicating that SLIV programs for adolescents tended to
be more challenging than those for elementary school
students [12].
Hypotheses 2 & 3: the effect of spillover
Another point of comparison is that our study consid-
ered spillover while others did not. Although Effler et al.
[22] reported lower cost components than our SLIV pro-
grams, their study did not consider a potential negative
spillover (reduction in practice-based vaccination) that
may have occurred because their large state-wide pro-
gram started October 15, much earlier than our program
in late November. If included, cost-effectiveness of the
SLIV program evaluated by Effler et al could have been
closer to ours. Similarly, none of the studies listed above
[20–24, 35] accounted for a potential spillover in their
cost estimations. Only two studies’ limitation sections
noted the absence of the data on a potential spillover,
[35] which is very important in designing an SLIV pro-
gram and coordinating with local primary care practices,
in addition to evaluating SLIV cost-effectiveness. As
noted previously, our SLIV programs offered clinics at
the end of November, after primary care practices had a
chance to vaccinate many school-aged patients and use
up their vaccine supplies [15, 16]. We chose this timing
deliberately to minimize potential negative spillover in
which SLIV might substitute for practice-based vaccina-
tions [8, 15, 16]. This likely worsened our SLIV pro-
gram’s cost-effectiveness because more students
probably would have been vaccinated at SLIV clinics
scheduled earlier in the influenza vaccination season and
fewer would have been vaccinated at primary care
practices.
Considering spillover would help discuss the SLIV’s
potential impact on disparity in vaccination rates
between urban (37.3% in control schools in Additional
file 1: Table A1) and suburban schools (48.3% in control
schools in Additional file 1: Table A1). SLIV decreased
such disparity between urban and suburban schools,
since SLIV’s secondary effectiveness measure was greater
in urban schools (7.2% in Additional file 1: Table A1,
bottom row) than suburban schools (2.9% in Additional
file 1: Table A1, bottom row). When accounting for
spillover, SLIV’s primary effectiveness measure was still
greater in urban schools (7.3% (=44.6–37.3%) in
Additional file 1: Table A1, third row) than suburban
schools (6.5% (=54.8–48.3%) in Additional file 1: Table
A1, third row). Comparing these two sets of effective-
ness measures, we found that the reduction in disparity
between urban and suburban schools was mainly due to
the vaccinations at the SLIV clinics rather than positive
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spillover (0.1% (=37.4–37.3%) in Additional file 1: Table
A1, fourth row, in primary care practices) among urban
schools. We did not report ICERs specific for urban and
suburban schools which were very similar and hence
provided little incremental implications.
Hypothesis 4: comparison with primary care practices and
other SLIV programs
Both our elementary SLIV program and our secondary
school SLIV program ($53.40–$86.51 per vaccinated
child) tend to be much less cost-effective than practice-
based influenza vaccination (median/mean = $25.50/
$45.48) [17, 19], even considering spillover. Only if we
additionally account for indirect averted parental costs
to visit primary care practices does our SLIV program in
secondary schools ($36.57) become equally or more cost
effective than primary care practices. Our SLIV pro-
grams --without considering spillover ($85.71–$86.51) --
appear much less cost-effective than other SLIV models
when applying the common “standardized program cost”
defined earlier (excluding the vaccine purchase cost) and
the secondary effectiveness measure: Schmier et al.
($8.03) [20], Hull et al. ($11.63) [21], Cho et al. ($14.93)
[34], Effler et al. ($18.01) [22], Kempe et al. ($28.40)
[23], Kwong et al.($23.40–$28.67) [24], and Kansagra
et al. ($91.41) [35]. Of note, among these studies, only
the studies by Cho et al. [34], Effler et al. [22], Kwong et
al. [24], and Kansagra et al. [35] reported the detailed
cost components that enable a more complete compari-
son with our SLIV programs.
However, caution is needed for these comparisons.
The study on primary care practices [17, 19] did not ex-
plicitly include the potential costs for reminders or other
costs paid by practices and insurers; our SLIV programs’
components costs (A) and (B) were assumed to be zero
in primary care practices. Such cost under-estimation
was true for other studies by Cho et al. [34] and Kwong
et al. [24]. The former study reported the coordination
cost in another publication ($18.27 per vaccinated child),
[23, 38] which was lower than our SLIV program’s com-
ponent cost (A + B = $61.41/$62.21 per-additionally-
vaccinated-child in elementary/secondary schools; not
presented in tables), but included some clinics without
assigning costs for donated materials and uncompen-
sated volunteer staff. In the latter study [24], their vac-
cine administration costs ($28.67/$23.40 for IIV/LAIV)
were comparable to or higher than our SLIV program’s
component cost (C), i.e., vendor’s vaccine administration
cost ($24.30 in Table 2).
Hypothesis 5: the effect of web-consent system
Compared to our 2009–2011 SLIV program with
paper-only consent, our 2015–2016 SLIV programs
with web-consent had lower component costs (A + B,
involved with consent processes), and improved cost-
effectiveness, only when considering spillover. The
web-consent system appears to have dissimilar im-
pacts on the differences in SLIV’s cost-effectiveness’s
numerator (i.e., effectiveness) and denominator (i.e.,
cost) between 2009 and 2011 and 2015–2016 SLIV
programs. Regarding SLIV’s effectiveness difference be-
tween 2009 and 2011 and 2015–2016, the web-
consent system seems to have a small contribution to
improving SLIV’s effectiveness. This was because use
of the web-consent system was not randomly assigned
and varied substantially across schools: 4% of urban
elementary schools, 73% of suburban secondary
schools. Such low use in urban schools may imply
that these schools were not ready for the web-based
consent. In contrast, SLIV’s cost difference between
the 2009–2011 and 2015–2016 was largely explained
by the additional cost for the web-consent system
($0.57 per eligible child and $12.97 per-additionally-
vaccinated-child in all SLIV schools; not presented in
tables) and its relevant project coordination cost. Al-
though we did not measure the project coordination
cost uniquely spent for the web-consent system (a
part of the component cost (B): $1.70 per eligible
child and $38.81 per-additionally-vaccinated-child in
all SLIV schools; not presented in tables), if this cost
was excluded, it is likely that our project coordination
costs would have been comparable to those of previ-
ous studies.
Limitations
Our study design could limit the generalizability of our
estimates. For instance, we used one county. Yet our
vaccination rates in elementary schools (38.9–57.9% in
Additional file 1: Table A2, third row) and secondary
schools (31.1–50.0% in Additional file 1: Table A3, third
row) were slightly lower than or comparable to vaccin-
ation rates reported nationally (61.8 and 46.8% for elem-
entary and secondary schools, respectively) [4]. It should
be noted that our vaccination estimates among elemen-
tary schools were county-representative, since we in-
cluded all students in these school districts [14]. Also,
we examined a relatively small number of secondary
schools, although our study population was still one of
the largest populations in published studies of SLIV.
Additionally, we purposefully scheduled SLIV clinics for
late in the vaccination season to allow practices to vac-
cinate many children, which affected the cost-
effectiveness of our SLIV programs as described earlier.
Finally, we were unable to obtain school absenteeism
rates for this study. However, studies funded by industry
(that included free vaccines and substantial labor sup-
port, and hence not as “real-world” as our study) have
evaluated school absenteeism with mixed results—for
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example King et al. found no impact on school absentee-
ism [39] whereas Pannaraj et al. did find an impact [40].
Conclusions
SLIV modestly raised vaccination rates in both elemen-
tary schools and secondary schools. SLIV caused positive
spillover, increasing practice-based vaccination in the
suburbs; this improved the effectiveness and cost-
effectiveness of SLIV and should be addressed by future
studies. Nevertheless, SLIV was costlier than practice-
based vaccination when only considering the cost-per-
additionally-vaccinated child and direct costs. SLIV was
comparable to (or less costly than) practice-based vac-
cination when additionally considering indirect costs
(lost parental income due to time lost from work). Con-
sidering only direct costs, to be as cost-effective as
practice-based vaccination, our SLIV programs would
need to vaccinate more students and/or lower project
coordination and web-consent system costs.
Additional file
Additional file 1: Additional Table A1. Vaccination rates in school-
located influenza vaccination program and control schools in 2015–2016.
Additional Table A2. Vaccination rates in school-located influenza
vaccination program in 2015–2016 (elementary schools only). Additional
Table A3. Vaccination rates in school-located influenza vaccination
program in 2015–2016 (secondary schools only). (DOCX 31 kb)
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